InvestorsHub Logo
Followers 826
Posts 119567
Boards Moderated 15
Alias Born 09/05/2002

Re: None

Wednesday, 09/06/2017 8:38:38 AM

Wednesday, September 06, 2017 8:38:38 AM

Post# of 866
MRK acquires private I-O company for €115M up-front and €349 in contingent milestone payments:

https://finance.yahoo.com/news/merck-acquire-rigontec-rig-therapeutics-103000725.html

Merck…and Rigontec today announced that Merck will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity.

Rigontec’s lead candidate, RGT100, is currently in Phase I development evaluating treatment in patients with various tumors.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRK News